StockNews.com began coverage on shares of Evogene (NASDAQ:EVGN – Free Report) in a report published on Saturday morning. The brokerage issued a sell rating on the biotechnology company’s stock.
Evogene Price Performance
NASDAQ:EVGN opened at $1.65 on Friday. The company has a market cap of $8.85 million, a P/E ratio of -0.37 and a beta of 1.36. The firm’s fifty day moving average price is $1.77 and its two-hundred day moving average price is $3.45. Evogene has a one year low of $1.20 and a one year high of $10.40.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Evogene stock. Renaissance Investment Group LLC acquired a new position in shares of Evogene Ltd. (NASDAQ:EVGN – Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Institutional investors and hedge funds own 10.40% of the company’s stock.
Evogene Company Profile
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
Featured Articles
- Five stocks we like better than Evogene
- 3 Best Fintech Stocks for a Portfolio Boost
- Buffett Takes the Bait; Berkshire Buys More Oxy in December
- Investing in the High PE Growth Stocks
- Top 3 ETFs to Hedge Against Inflation in 2025
- Dividend Capture Strategy: What You Need to Know
- These 3 Chip Stock Kings Are Still Buys for 2025
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
